ATAI Beckley (ATAI) said Thursday it that the US Patent and Trademark Office has granted a new patent covering EMP-01, which is intended to treat social anxiety disorder.

The patent includes claims to the drug substance of EMP-01 and is expected to provide exclusivity through 2043. It also protects critical drug substance attributes of the drug candidate.

Shares of the company rose more than 2% in recent premarket activity Thursday.

Price: 4.43, Change: +0.10, Percent Change: +2.31